Clinical Trial Update: A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome [Phase 3]

View source ↗

Summary

A Phase 3 trial of BPN14770 in adult males with Fragile X Syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fragile Syndrome

Drugs mentioned

• BPN14770

Snippet

Sponsor: Tetra Discovery Partners | Conditions: Fragile X Syndrome | Phase 3 | Status: COMPLETED